3

AM-1638

3 Cited Publications

Cat. No.: HY-13467

CAS No.: 1142214-62-7

Purity: 99.65%

Target:

Free Fatty Acid Receptor

Research Areas:

Metabolic Disease

AM-1638 is an orally active full agonist of GPR40 (EC₅₀: 0.16 μM). AM-1638 increases the expression of antioxidant molecules (HO-1 and NQO-1). AM1638 blocks Palmitate (HY-N0830)-mediated superoxide production and ER stress. AM-1638 has antidiabetic activity and improves glycemic control in BDF mice with diet-induced obesity (DIO). AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

AMG 837 calcium hydrate

3 Cited Publications

Cat. No.: HY-13967B

CAS No.: 1259389-38-2

Purity: 99.00%

Target:

Bacterial Free Fatty Acid Receptor

Research Areas:

Metabolic Disease

AMG 837 calcium hydrate is an orally active, selective GPR40/FFA1 agonist with an EC₅₀ of 1.5 nM against human GPR40. AMG 837 calcium hydrate stimulates insulin secretion in a glucose-dependent manner, and effectively improves glycemic control in both normal and diabetic rodent models . AMG 837 calcium hydrate binds to the BacA protein and impairs the survival and replication of Brucella. AMG 837 calcium hydrate can be used in research related to type 2 diabetes and brucellosis .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

AMG 837

3 Cited Publications

Cat. No.: HY-13967

CAS No.: 865231-46-5

Target:

Free Fatty Acid Receptor Bacterial

Research Areas:

Infection Metabolic Disease

AMG 837 is an orally active, selective GPR40/FFA1 agonist with an EC₅₀ of 1.5 nM against human GPR40. AMG 837 stimulates insulin secretion in a glucose-dependent manner, and effectively improves glycemic control in both normal and diabetic rodent models . AMG 837 binds to the BacA protein and impairs the survival and replication of Brucella. AMG 837 can be used in research related to type 2 diabetes and brucellosis .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Beinaglutide

1 Cited Publications

Cat. No.: HY-P3463

CAS No.: 123475-27-4

Synonyms: GLP-1 (human)

Target:

GCGR

Research Areas:

Metabolic Disease Inflammation/Immunology

Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Trelagliptin

1 Cited Publications

Cat. No.: HY-15408

CAS No.: 865759-25-7

Purity: 99.54%

Synonyms: SYR-472

Target:

Dipeptidyl Peptidase

Research Areas:

Metabolic Disease

Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

1,5-Anhydrosorbitol

1 Cited Publications

Cat. No.: HY-113075

CAS No.: 154-58-5

Purity: 99.57%

Synonyms: 1,5-Anhydro-D-glucitol

Category:

Immune System Disorder Disease markers Metabolic Disease Endocrine diseases Endogenous metabolite Disease Research Fields Saccharides

Target:

Endogenous Metabolite

1,5-Anhydrosorbitol is a short-term marker for glycemic control.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Trelagliptin succinate

1 Cited Publications

Cat. No.: HY-15408A

CAS No.: 1029877-94-8

Purity: 99.96%

Synonyms: SYR-472 succinate

Target:

Dipeptidyl Peptidase

Research Areas:

Metabolic Disease

Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

ZP3022

1 Cited Publications

Cat. No.: HY-P10341

CAS No.: 1345835-12-2

Target:

GLP Receptor Cholecystokinin Receptor

Research Areas:

Metabolic Disease

ZP3022 is a dual GLP-1R/CCK-2R agonist. ZP3022 enhances insulin secretion, improves glycemic control and glucose tolerance, lowers blood glucose and HbA1c levels, reduces food intake and body weight, and inhibits gastric emptying. ZP3022 does not activate CCK-1R. ZP3022 can be used in research on diabetes and obesity .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Icovamenib

Cat. No.: HY-150105

CAS No.: 2448172-22-1

Purity: 98.72%

Synonyms: BMF-219; Menin-MLL inhibitor 21

Target:

Epigenetic Reader Domain

Research Areas:

Metabolic Disease Inflammation/Immunology Cancer

Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Amylose

Cat. No.: HY-W145665

CAS No.: 9005-82-7

Category:

Human Gut Microbiota Metabolites Polysaccharides Other Diseases Endogenous metabolite Disease Research Fields Saccharides

Target:

Biochemical Assay Reagents Endogenous Metabolite

Amylose is not a typical small-molecule ligand with a specific traditional receptor-binding target. It is a polysaccharide. In food science and biological systems, amylose can interact with proteins and free fatty acids through non-covalent forces like hydrophobic interactions and electrostatic interactions. For example, it can form a ternary complex with them, which is related to the structure and digestion of starch. It is widely studied in the fields of food science, carbohydrate metabolism, and is also relevant in research on controlling glycemic responses, as it affects starch digestion rate .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Colesevelam hydrochloride

Cat. No.: HY-106539

CAS No.: 182815-44-7

Purity: ≥95.0%

Target:

FXR G protein-coupled Bile Acid Receptor 1 GLP Receptor

Research Areas:

Metabolic Disease Cancer

Colesevelam hydrochloride is an orally active bile acid sequestrant, lipid-lowering agent, and glycemic control agent. Colesevelam hydrochloride binds bile acids in the gastrointestinal tract to form nonabsorbable complexes, interrupts enterohepatic recirculation and increases fecal bile acid elimination. Colesevelam hydrochloride modulates FXR, TGR5, and Cyp7a1 activity and triggers cAMP signaling and GLP-1 release. Colesevelam hydrochloride alters hepatic lipid and glucose metabolism, suppresses hepatic glycogenolysis, reduces hepatic triglyceride and cholesterol levels, and increases LDL-C (low-density lipoprotein cholesterol) clearance. Colesevelam hydrochloride can be used for the research of type 2 diabetes mellitus, hypercholesterolemia, and alcohol-related liver disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Ragaglitazar

Cat. No.: HY-16421

CAS No.: 222834-30-2

Synonyms: (-)-DRF 2725; NNC 61-0029

Target:

PPAR

Research Areas:

Metabolic Disease

Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

Compare

loading...